




FIG. 1

Figure 1

FIG. 2




FIG. 3A





FIG. 3B






FIG. 4




FIG. 6A




FIG. 6B




FIG. 6C




FIG. 6D

FIG. 6E





FIG. 6F






FIG. 6I





Figure 6J







FIG. 7

FIG. 8A

Soluble TACI-Fc

**FIG. 8B**

Soluble TACI-Fc








FIG. 9

TACI 122	MSG LGRSRRGGRSRVDQEERFPQGLWTGVAMRSCPEEQYWDPLLGTCTMCKTICNHQSQR	60
TACI 13	-----	0
TACI 122	TCAAFCRSLSCRKEQGKFYDHLRLRDCISCA SICGQHPKQCA YFCENKLRSPVNLPPELRR	120
TACI 13	-----SLSCRKEQGKFYDHLRLRDCISCA SICGQHPKQCA YFCENKLR-----	43

TACI 122	Q RSGEVENNSD NSGRYQGLEH RGS EAS PALPGLKLSADQVALVYST	166
TACI 13	-----	43



1. Fc Control

2. TACI 30-110 – Fc

3. TACI 13-118 – Fc


4. 26 TACI CRD2-Fc
5. 27 TACI CRD2-Fc

6. 29 TACI CRD2-Fc

7. Naïve

FIG. 11A

FIG. 11B









FIG. 12







1. Fc Control
2. TACI 30-110 – Fc
3. TACI 13-118 – Fc
4. 26 TACI CRD2-Fc
5. 27 TACI CRD2-Fc
6. 29 TACI CRD2-Fc
7. Naïve

FIG. 15

FIG. 16B




FIG. 16A




FIG. 17B





FIG. 17A



Serum Ig concentration over time




FIG. 18




FIG. 19

FIG. 20B





FIG. 20A






FIG. 21





FIG. 22






FIG. 24

FIG. 25A





FIG. 25B









FIG. 25C



† Mice received 6 doses of each test article twice weekly (10 mg/kg)




FIG. 28

FIG. 29 B




FIG. 29 A




Figure 30




FIG. 30






FIG. 31



- 1. Fc Control
- 2. 26 TACI CRD2-Fc
- 3. WT TACI-Fc
- 4. Naïve BL/6

FIG. 32



- 1. Fc Control
- 2. 26 TACI CRD2-Fc
- 3. WT TACI-Fc
- 4. Naïve BL/6

FIG. 33









FIG. 34








FIG. 37




FIG. 38




FIG. 39




FIG. 40




FIG. 41




FIG. 42